Astellas Acquires Propella Therapeutics for ~$175M

Share this

Astellas Acquires Propella Therapeutics for ~$175M


  • Both Astellas and Propella have entered into a merger agreement as per which Astellas has reported the acquisition of Propella
  • Under the terms of the agreement, Astellas will pay an aggregate of ~$175M to acquire all the outstanding common stocks and equity interests in Propella. The transaction is expected to occur during FY Mar 31st 2024
  • Following the acquisition, Propella's androgen biosynthesis inhibitor, PRL-02, which is currently being evaluated in a P-I clinical trial for the treatment of prostate cancer, will come under the purview of Astellas. PRL-02 is expected to enter P-IIa trial in 2024

Ref: PR Newswire | Image: Propella

Related News:- Propella Signs a License Agreement with Jiangsu Aosaikang to Develop and Commercial CGS-200-5 for the Treatment of Pain in Greater China

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions